Technology | June 23, 2008

1,300th TandemHeart System Procedure Completed


June 25, 2008 - Cardiologists completed the 1,300th worldwide procedure utilizing the TandemHeart System, said manufacturer CardiacAssist, marking the increased acceptance of the device and use by cardiologists and surgeons.

The TandemHeart System assists heart failure patients survive both heart attacks and high risk procedures, while providing versatility to physicians in choosing the time, place and type of treatments. The system has a high net flow rate of up to 5 lpm in the Cath Lab or up to 8 lpm in the OR as well as its flexibility and rapid deployment potential. There are a variety of FDA cleared devices that provide extracorporeal circulatory support, but all others offer less than half the net flow and hemodynamic support of the TandemHeart System.

The TandemHeart System is now used in over 100 heart centers across the U.S. Ten prestigious heart centers were recently active in helping CardiacAssist, Inc. surpass the 1,300th procedure for its TandemHeart System. These 10 heart centers include:

-- Brigham & Women's Hospital in Boston, MA

-- Cleveland Clinic in Cleveland, OH

-- Hospital of the University of Pennsylvania in Philadelphia, PA.

-- Lahey Clinic in Burlington, MA

-- Lenox Hill in New York City, NY

-- Mayo Clinic in Rochester, MN

-- Mt. Sinai in New York City, NY

-- Sacred Heart Medical Center in Spokane, WA

-- St. Luke's Hospital in Kansas City, MO

-- Texas Heart Institute in Houston, TX

The TandemHeart System is fully reimbursed by Medicare under existing DRG codes. The device can be placed rapidly in the cath lab or operating room, providing effective, reliable, temporary circulatory support for critically ill patients.

For more information: www.cardiacassist.com


Related Content

News | Ventricular Assist Devices (VAD)

June 19, 2024 — When electrophysiologist Eugenio Cingolani, MD, isn’t seeing patients, he can usually be found in his ...

Home June 19, 2024
Home
News | Ventricular Assist Devices (VAD)

October 31, 2023 — Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop ...

Home October 31, 2023
Home
News | Ventricular Assist Devices (VAD)

June 7, 2023 — Magenta Medical Ltd. has announced the initiation of its FDA-approved Early Feasibility Study with the ...

Home June 07, 2023
Home
News | Ventricular Assist Devices (VAD)

March 1, 2023 — Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, today ...

Home March 01, 2023
Home
News | Ventricular Assist Devices (VAD)

November 2, 2022 — For decades, left ventricular-assist devices (LVADs) have extended the lives of people whose hearts ...

Home November 02, 2022
Home
News | Ventricular Assist Devices (VAD)

October 18, 2022 — The U.S. Food and Drug Administration (FDA) is providing updates to the FDA website to include ...

Home October 18, 2022
Home
News | Ventricular Assist Devices (VAD)

August 25, 2022 — The U.S. Food and Drug Administration (FDA) issued a statement that Medtronic, Inc. is recalling ...

Home August 25, 2022
Home
News | Ventricular Assist Devices (VAD)

August 5, 2022 — Black people and women with severe heart failure who might be good candidates for surgery to implant a ...

Home August 05, 2022
Home
News | Ventricular Assist Devices (VAD)

June 23, 2022 — Medtronic, Inc. is recalling a single lot of HeartWare HVAD System batteries due to welding defects that ...

Home June 23, 2022
Home
News | Ventricular Assist Devices (VAD)

June 8, 2022 — The U.S. Food and Drug Administration (FDA) has issued a release stating that Medtronic is recalling the ...

Home June 08, 2022
Home
Subscribe Now